COMPANY PROFILE // THE 014 REPORT

Aclaris Therapeutics, Inc.

ACRS (Nasdaq)

Assembled from 4 government sources in 0.1 s

Built from public records at 2026-11-19 17:34 ET. Every figure links to its source. Flags and checks built 2026-11-19 21:21 ET. Sources

FLAGS · DISCLOSURE · SUMMARY

Missing or hidden

  • AmberLEI 5493000B2LQ9QTW1DF52 registration status is LAPSED (last update 2026-10-25): the legal-entity record has not been renewed.2026-10-25 · source
  • InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.2026-11-19 · source

✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration

No SAM registration, no IRS return, no website, no lobbying registration on record.

Aclaris Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Wayne, PA; listed as ACRS (Nasdaq).[source] It reported revenue of $7.8 million for the fiscal year ended 2025-12-31.[source] It has filed 62 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: LEI 5493000B2LQ9QTW1DF52 registration status is LAPSED (last update 2026-10-25).[source]

0federal award recipients matched by name in USAspending
0lobbying filings name it as client
62SEC filings in the last 12 months
$391.3Mheld by its 10 largest 13F holders (as of 2026-06-30)
SEC filings by month, 24 months
2024-12: 102025-01: 52025-02: 102025-03: 62025-04: 62025-05: 82025-06: 92025-07: 42025-08: 42025-09: 02025-10: 12025-11: 32025-12: 12026-01: 72026-02: 172026-03: 52026-04: 72026-05: 42026-06: 72026-07: 02026-08: 62026-09: 12026-10: 32026-11: 42024-122026-11
Flags by level
  • red0
  • amber1
  • info1
Largest 13F holders, value as filed
  • RA CAPITAL MANAGEMENT, L.P.$67.3M
  • BML Capital Management, LLC$63.3M
  • BlackRock, Inc.$53.1M
  • Deep Track Capital, LP$49.4M
  • Vivo Capital, LLC$35.4M
  • VANGUARD CAPITAL MANAGEMENT LLC$30.8M
  • Frazier Life Sciences Management, L.P.$26.1M
  • Rock Springs Capital Management LP$22.9M

RECORD · WEB

Ask about this entity

Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).

PEOPLE · COUNSEL · LINKS

Leadership, advisers and links

Officers and directors (Forms 3, 4, 5)

As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.

Legal counsel, as publicly named

EVERY LIST AND SOURCE · DATED

Checked and clear

26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.

List or sourceResultCheckedWhat matched
OFAC SDN (Treasury)CLEAR2026-11-18
SAM.gov exclusionsCLEAR2026-11-19
HHS-OIG LEIECLEAR2026-11-13
FARA registrants (DOJ)CLEAR2026-11-19
Regulated facility: compliance, penalties and TRI parent (EPA)CLEAR2026-11-18
Hazardous-waste handler facility (EPA RCRAInfo, sample)CLEAR2026-11-18
Consumer complaints about a company (CFPB)CLEAR2026-11-18
Corporate enforcement action (DOJ, SEC, CFTC, EPA)CLEAR2026-11-18
SEC litigation release (respondent)CLEAR2026-11-18
Federal Reserve Board enforcement action (press release, 2022 onward)CLEAR2026-11-18
Enforcement order against a savings association (OCC, OTS archive to 2011)CLEAR2026-11-18
State environmental enforcement actions (Maryland MDE, Connecticut DEEP)CLEAR2026-11-18
Firm sanctioned or debarred by the IDB Group (incl. cross-debarments by WBG, ADB, EBRD, AfDB as listed by the IDB)CLEAR2026-11-18
UK sanctions designation (FCDO UK Sanctions List)CLEAR2026-11-18
US export screening list party (Consolidated Screening List, ITA)CLEAR2026-11-18
FDA recallCLEAR2026-11-18
FDA import alert or listed firm (Red / Yellow / Green list)CLEAR2026-11-18
Consumer product recall or recalling firm (CPSC, full history)CLEAR2026-11-18
Consumer product recall (CPSC)CLEAR2026-11-18
Vehicle recall, defect investigation or manufacturer (NHTSA ODI)CLEAR2026-11-18
Vehicle recall (NHTSA)CLEAR2026-11-18
FinCEN enforcement action (civil money penalty or consent order, 1999 onward)CLEAR2026-11-18
Union representation election (NLRB)CLEAR2026-11-18
NYC summons against an organization, adjudicated at OATH (all city agencies)CLEAR2026-11-18
Data breach notice to a state Attorney GeneralCLEAR2026-11-18
Data breach notice (California Attorney General)CLEAR2026-11-18

EVERY IDENTIFIER · LINKED

ID crosswalk

IdentifierValueRecord
SEC CIK0001557746source
LEI5493000B2LQ9QTW1DF52source
EIN46-0571712source
Business address (SEC)701 LEE ROAD, WAYNE, PA, 19087source

Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.

EACH FEEDS WATCH

Dates coming up

PEERS BY SIC CODE

Industry context

SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.

#42 of 568
federal dollars
#40 of 568
lobbying filings
#265 of 568
SEC filings in 12 months
#200 of 568
flags

Peers, each with its 014

  • PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
  • Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
  • ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
  • ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
  • NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
  • Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
  • Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
  • SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
  • Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
  • UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
  • Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)

SHARED PEOPLE · SHARED ADDRESS

Network neighbours

Shared directors and officers

EVERY SOURCE · NEWEST FIRST

One timeline

121 earlier entries

RENDERED FROM THIS PAGE

Relationship graph

Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.

DATA MOTION // NEWEST FIRST

What changed

Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.

COUNTS FROM THIS PAGE

Relationships at a glance

10largest institutional holders (13F as filed)
0other entities in the GLEIF ownership tree (ID tier)
0awarding federal agencies
0hiring lobbying firms: possible match: matched by name only, not merged
PRICE · FILINGS · POSTS · NEWS

Market & news

Price
NASDAQ:ACRS The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
Open in
Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

Financials
Filed figures: published SEC values, each linked to its filing.
Official posts
Links to posts from the company's and agencies' verified accounts: not connected yet.
News
Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER

1. Identity

2confirmed members (SEC registrant + GLEIF ownership tree)
1legal entities (LEI) in the ownership tree
27dated filings and events

2 possible matches held apart, matched by name only, not counted above.

IdentifierValueHow it was resolvedSource
SEC CIK1557746id:sec-anchor: the SEC registrant record of this companySEC EDGAR
Ticker / exchangeACRS / NasdaqSEC company record: ticker and exchange as listed on the SEC company recordSEC EDGAR
LEI (root of the ownership tree)5493000B2LQ9QTW1DF52id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 5493000B2LQ9QTW1DF52)GLEIF
EIN460571712carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001557746SEC EDGAR / IRS
CUSIP00461U105carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001557746SEC EDGAR
AS FILED · EACH WITH ITS DATE AND FILING

2. Filed figures

Key figures (annual filing)

FigureValuePeriod or as ofSourceBasisRetrievedReport
Revenue (fiscal year ended 2025-12-31)$7,826,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTaxas filed2026-11-19 22:34 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)-$64,923,0002025-12-3110-K, XBRL NetIncomeLossas filed2026-11-19 22:34 UTCReport an error
Total assets (at 2025-12-31)$160,460,0002025-12-3110-K, XBRL Assetsas filed2026-11-19 22:34 UTCReport an error
Stockholders' equity (at 2025-12-31)$103,082,0002025-12-3110-K, XBRL StockholdersEquityas filed2026-11-19 22:34 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$19,960,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValueas filed2026-11-19 22:34 UTCReport an error

Company profile facts (SEC)

FigureValuePeriod or as ofSourceBasisRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error
Business address701 LEE ROAD, SUITE 103, WAYNE, PA, 190872026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profileas filed2026-11-19 22:34 UTCReport an error

Other filed values

FigureValuePeriod or as ofSourceBasisRetrievedReport
Operating cash flow (fiscal year ended 2025-12-31)-$47,113,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivitiesas filed2026-11-19 22:34 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$111,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipmentas filed2026-11-19 22:34 UTCReport an error
Operating lease liabilities (at 2025-12-31)$2,116,0002025-12-3110-K, XBRL OperatingLeaseLiabilityas filed2026-11-19 22:34 UTCReport an error
Form D total offering amount (D filed 2024-12-04)$79,999,9992024-12-04Das filed2026-11-19 22:34 UTCReport an error
Form D total amount sold (D filed 2024-12-04)$79,999,9992024-12-04Das filed2026-11-19 22:34 UTCReport an error
Form D industry groupPharmaceuticals2024-12-04Das filed2026-11-19 22:34 UTCReport an error
Form D revenue rangeDecline to Disclose2024-12-04Das filed2026-11-19 22:34 UTCReport an error
Form D date of first sale2024-11-192024-12-04Das filed2026-11-19 22:34 UTCReport an error
Plan (pension, plan no. 001)ACLARIS THERAPEUTICS INC 401(K) PLAN: 118 participants, assets $16,165,4982025-12-31DOL EBSA Form 5500 public datasets (dataset)as filed2026-11-19 22:34 UTCReport an error

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123374

ItemValuePeriodFormFiledAccessionRetrievedReport
Revenue$1,481,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-19 22:34 UTCReport an error
Net income (loss)-$18,510,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-19 22:34 UTCReport an error
Cash and cash equivalents$20,394,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-19 22:34 UTCReport an error
Contract liabilities, current$3,966,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-19 22:34 UTCReport an error
Contract liabilities, noncurrent$13,334,000at 2026-09-3010-Q2026-11-050001104659-26-1233742026-11-19 22:34 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.

No estimates: every value is as filed and links to the filing it came from.

Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.

NEWEST FIRST · EACH LINKS TO ITS FILING

3. Registration and filing timeline

2 earlier entries

8-K item text, as filed (excerpts)

Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.

AS FILED · LARGEST HOLDERS

10. 13F institutional holders

RankHolder (13F filer)Value heldAs ofSourceRetrievedReport
1RA CAPITAL MANAGEMENT, L.P.$67,304,8082026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
2BML Capital Management, LLC$63,347,7502026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
3BlackRock, Inc.$53,095,7722026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
4Deep Track Capital, LP$49,435,0502026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
5Vivo Capital, LLC$35,414,6302026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
6VANGUARD CAPITAL MANAGEMENT LLC$30,776,5112026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
7Frazier Life Sciences Management, L.P.$26,055,2282026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
8Rock Springs Capital Management LP$22,908,5142026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
9ADAGE CAPITAL PARTNERS GP, L.L.C.$21,535,5902026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error
10Decheng Capital LLC$21,380,7832026-06-30SEC 13F filing2026-11-19 22:34 UTCReport an error

13F as filed: the holder's own report of its position value at the quarter end.

GLEIF OWNERSHIP TREE · ID TIER

11. Subsidiaries

1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).

Exhibit 21 subsidiaries: not held yet.

POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS

13. Permits and local records

2 state and city records carry this company's exact name, from 2 sources. Possible matches only.

ClinicalTrials.gov (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

State licences (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

WHAT THIS PAGE READ

Sources

As of 2026-11-19 (record built 2026-11-19T22:34:37Z). Sources used: SEC EDGAR, DOL EBSA Form 5500 public datasets, SEC 13F holdings, GLEIF.

Not checked: FTC enforcement actions; DOJ press releases (beyond FARA and the corporate enforcement set); federal and state court records; UCC filings, liens and bankruptcy dockets; IRS automatic revocation list; state annual-report dates; company formation dates (only where a state registry record states one).

JSON · MCP · API

API and agents

The same profile as JSON: GET /company/1557746.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001557746. Every source URL used is listed in the file.

Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.